ORIGINAL ARTICLE: A COMPREHENSIVE STUDY OF PROSTATIC LESIONS AND ITS PROSTATE-SPECIFIC ANTIGEN LEVELS IN ANATOMICAL PATHOLOGY INSTALLATION OF RSUD DR. SOETOMO, SURABAYA FROM YEAR 2014 TO 2016
Abstract
Abstract. Background: Diseases primarily affects prostate gland are inflammation, hyperplasia, and malignant tumour. Gleason score (GS) is an essential facet and together with PSA are substantial in diagnosing, managing, and determining the prognosis of CaP. Purpose: The aims of this study is to investigate the prevalence of prostatic lesions and its PSA level among patients in anatomical pathology installation in RSUD Dr. Soetomo from year 2014 to 2016. Method: This research is a retrospective study of prostatic lesions that were conducted from year 2014 to 2016 (3 years) with emphasis on GS and PSA levels. Result: The distribution of histopathological lesion found are benign lesion, benign prostate hyperplasia, adenocarcinoma, prostatitis, benign prostate hyperplasia with prostatitis, prostatic intraepithelial neoplasia, non-Hodgkin lymphoma, sarcoma, transitional cell carcinoma, and squamous cell carcinoma. The most common findings in this cohort is benign lesion (34.6%) with age group of 61-70 years old (51.94%) and adenocarcinoma with high GS of 9 (60%). Meanwhile, patients with GS >8 (high risk patient) contributed for 84.8%. Most of the cases (69.2%) have elevated PSA level of > 20 ng/ml. Conclusion: The prevalence of prostatic lesions were able to be determined in different age groups. High GS indicates a more aggressive type of adenocarcinoma suffered, high risk for CaP. The results show that the possibility to detect malignancy with rising PSA level are higher, although PSA is not considered as a specific marker.
Keywords: prostate, histopathology, benign lesion, PSA.
Keywords
References
References
Nwafor, C., Keshinro, O. and Abudu, E. (2015). A histopathological study of prostate lesions in Lagos, Nigeria: A private practice experience. Nigerian Medical Journal, 56(5), p.338.
Kumar, V., Abbas, A., Aster, J. and Perkins, J. (2007). Robbins basic pathology. 7th ed. Philadelphia: Elsevier.
Aslam H, Shahid N, Shaikh N, Shaikh H, Saleem S, Mughal A. Spectrum of prostatic lesions. International Archives of Medicine [Internet]. 2013 [cited 8 September 2017];6(1):36. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1186%2F1755-7682-6-36
Dabir P, Ottosen P, Høyer S, Hamilton-Dutoit S. Comparative analysis of three- and two-antibody cocktails to AMACR and basal cell markers for the immunohistochemical diagnosis of prostate carcinoma. Diagnostic Pathology. 2012;7(1):81.
Al-Samawi, A.S., M.Phill, and Aulaqi, S.M., (2014). The histopathological pattern of prostatic disease and prostatic cancer in Yemeni patients. Sana’a University Journal od Medical Sciences. [online] 6(1) [Accessed 24 Sept. 2017].
Dickinson, S. (2010). Premalignant and Malignant Prostate Lesions: Pathologic Review. Cancer Control, [online] 17(4), pp.214-222. Available at: https://www.ncbi.nlm.nih.gov/pubmed/20861809 [Accessed 10 Oct. 2017].
Albasri A, El-Siddig A, Hussainy A, Mahrous M, Alhosaini A, Alhujaily A. Histopathologic Characterization of Prostate Diseases in Madinah, Saudi Arabia. Asian Pacific Journal of Cancer Prevention. 2014;15(10):4175-4179.
Algaba F. Pitfalls of Pathologic Staging in Prostate Cancer. European Urology Supplements. 2008;7(1):6-14.
George, E. and Thomas, S., (2005) A Histopathologic Survey Of Prostate Disease In The Sultanate Of Oman. The Internet Journal of Pathology, 3(2).
Chang, A.J., Autio, K.A., Roach, M., Scher, H.I. (2014). “High-Risk” Prostate Cancer: Classification and Therapy [online] 11(6), p. 308-323. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508854/ [Accessed on 12 Dec. 2017]
Ross M, Pawlina W. Histology. 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health; 2011.
Ross, M. and Pawlina, W. (2011). Histology. 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health, pp.808-812.
Ross, M. and Pawlina, W. (2011). Histology. 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health, pp.808-812.
DOI: 10.24815/jks.v19i1.18049
Refbacks
- There are currently no refbacks.